secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001193125-23-050813
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD amends CEO Walker's employment; enters consulting agreement with former CFO Donegan
--------------------------------------------------------------------------------

- CEO Walker's base salary increased to $500k after Apr 15, 2023; receives $20,909 lump-sum bonus and 70,000 RSUs.
- Enhanced severance: 18 months salary, 1.5x target bonus, 24 months COBRA, full equity vesting on termination without cause or for good reason.
- Former interim CFO Donegan to provide consulting services as PFO/PAO via MCD Consulting; receives $100k signing fee, $50k/month, and 50,000 RSUs.
- Consulting agreement anticipated to end March 31, 2023; if extended, hourly rate $205.28; additional $100k fee on termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/0001193125-23-050813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523050813/d372195d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-050813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer